Module 1: Angiogenesis Inhibitors

Question 1

Treatment option for kidney cancer

Answer 1

Axitinib (Inlyta)

Question 2

Treament option for colorectal, kidney, and lung cancers

Answer 2

Bevacizumab (Avastin)

Question 3

Treatment option for medullary thyroid cancer and kidney cancer

Answer 3

Cabozantinib (Cometriq)

Question 4

Treatment option for kidney cancer, advanced breast cancer, pancreatic neuroendocrine tumors (PNETs), and subependymal giant cell astrocytoma, which is a rare type of noncancerous brain tumor

Answer 4

Everolimus (Afinitor, Zortress)

Question 5

Treatment option for multiple myeloma, tumors involving cells that normally produce antibodies, and mantle cell lymphoma, which is a type of non-Hodgkin lymphoma

Answer 5

Lenalidomide (Revlimid)

Question 6

Treatment option for endometrial carcinoma, hepatocellular carcinoma, renal cell carcinoma, and thyroid cancer

Answer 6

Lenvatinib Mesylate (Lenvima)

Question 7

Treatment option for kidney cancer and advanced soft tissue sarcoma

Answer 7

Pazopanib (Votrient)

Question 8

Treatment option for advanced stomach cancer; gastroesophageal junction adenocarcinoma, a cancer located where the stomach joins the esophagus; colorectal cancers; and non-small cell lung cancers

Answer 8

Ramucirumab (Cyramza)

Question 9

Treatment option for colorectal cancer and gastrointestinal stromal tumors (GIST)

Answer 9

Regorafenib (Stivarga)

Question 10

Treatment option for kidney, liver, and thyroid cancers

Answer 10

Sorafenib (Nexavar)

Question 11

Treatment option for kidney cancer, PNETs, and GIST

Answer 11

Sunitinib (Sutent)

Question 12

Treatment option for multiple myeloma. Women who are pregnant should not take this drug because it is proven to harm fetuses.

Answer 12

Thalidomide (Synovir, Thalomid)

Question 13

Treatment option for medullary thyroid cancer

Answer 13

Vandetanib (Caprelsa)

Question 14

Treatment option for colorectal cancer

Answer 14

Ziv-aflibercept (Zaltrap)